How to buy Reneo Pharmaceuticals stock (Reneo Pharmaceuticals)

Reneo Pharmaceuticals is a biotechnology business based in the US. Reneo Pharmaceuticals shares (RPHM) are listed on the NASDAQ and all prices are listed in US Dollars. Reneo Pharmaceuticals employs 8 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Reneo Pharmaceuticals stock

Buy Reneo Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Reneo Pharmaceuticals stock price (NASDAQ: RPHM)

Use our graph to track the performance of RPHM stocks over time.

Reneo Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-01.

52-week range	$12.50 - $19.30
50-day moving average more info button	$14.92
200-day moving average more info button	$16.09
Wall St. target price	$2.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-16.80

Is it a good time to buy Reneo Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Reneo Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-33.72%
Return on equity TTM	-54%
Profit margin	0%
Book value	$23.00
Market Capitalization more info button	$60.8 million

TTM: trailing 12 months

Reneo Pharmaceuticals share dividends

We're not expecting Reneo Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Have Reneo Pharmaceuticals's shares ever split?

Reneo Pharmaceuticals's shares were split on a 1:10 basis on 6 October 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Reneo Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Reneo Pharmaceuticals shares which in turn could have impacted Reneo Pharmaceuticals's share price.

Reneo Pharmaceuticals share price volatility

Over the last 12 months, Reneo Pharmaceuticals's shares have ranged in value from as little as $12.501 up to $19.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reneo Pharmaceuticals's is 0.22. This would suggest that Reneo Pharmaceuticals's shares are less volatile than average (for this exchange).

To put Reneo Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Atara Biotherapeutics (ATRA.US): 0.495
• Generation Bio Co (GBIO.US): 2.818
• Akouos Inc (AKUS.US): -0.5613

Reneo Pharmaceuticals overview

Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California. .

Frequently asked questions

What percentage of Reneo Pharmaceuticals is owned by insiders or institutions?
Currently 5.188% of Reneo Pharmaceuticals shares are held by insiders and 87.751% by institutions. How many people work for Reneo Pharmaceuticals?
Latest data suggests 8 work at Reneo Pharmaceuticals. When does the fiscal year end for Reneo Pharmaceuticals?
Reneo Pharmaceuticals's fiscal year ends in December. Where is Reneo Pharmaceuticals based?
Reneo Pharmaceuticals's address is: 18575 Jamboree Road, Irvine, CA, United States, 92612 What is Reneo Pharmaceuticals's ISIN number?
Reneo Pharmaceuticals's international securities identification number is: US75974E1038